Table 2 Clinical characteristics of the patients with rare GCK missense variants identified in the Pinggu cohort

From: A new clinical screening strategy and prevalence estimation for glucokinase variant-induced diabetes in an adult Chinese population

Individual no.

01-01a

02-01a

03-01a

04-01a

05-01a

06-01a

07-01a

08-01a

12-01b

13-01b

14-01b

15-01c

Variants

Thr82Pro

Arg377Leu

Gly44Ser

Ala259Ser

Arg43His

Arg250Cys

Gly44Ser

Thr354Met

Asp135Glu

Thr354Met

Asp135Glu

Gly318Arg

Age at recruitment, years

52

62

72

47

28

59

39

48

65

58

61

32

Age at diagnosis, years

52

62

72

47

28

59

39

48

64

57

45

N

Therapy

N

N

N

N

N

N

N

N

OHA + insulin

OHA

Insulin

N

Gender

Male

Male

Male

Female

Male

Female

Female

Male

Female

Female

Male

Female

Family history

N

Y

N

Y

N

N

Y

N

N

N

N

N

History of hypertension

Y

Y

N

N

N

Y

N

N

N

N

N

N

BMI, kg/m2

23.1

24.7

23.1

27.4

29.9

40.8

23.2

31.8

25.1

28.1

26.0

23.0

Waist circumference, cm

78.0

85.7

85.5

91.0

104.0

120.9

69.0

110.0

84.0

88.0

98.0

82.0

Blood pressure, mmHg

139/89

146/87

105/59

150/100

124/81

180/119

123/77

140/100

150/100

140/80

120/78

106/84

FPG, mmol/L

7.07

6.67

6.65

6.69

7.64

9.80

7.85

13.66

7.55

7.77

5.27

5.51

2-h PG, mmol/L

8.72

10.55

9.51

10.19

7.69

17.65

12.98

21.02

-

-

-

4.97

2-h glucose increment, mmol/L

1.65

3.88

2.86

3.50

0.05

7.85

5.13

7.36

-

-

-

–0.54

HbA1c, % (mmol/mol)

6.2 (44)

6.9 (52)

6.7 (50)

7.2 (55)

6.1 (43)

7.8 (62)

7.0 (53)

9.2 (77)

6.5 (48)

7.6 (60)

9.3 (78)

5.8 (40)

GA, %

17.6

18.1

18.3

17.3

16.9

23.2

18.4

27.4

17.1

20.3

23.0

14.5

Fins, pmol/L

10.70

28.20

39.93

87.85

66.39

148.69

22.57

183.90

111.40

52.09

485.66

68.89

Pins, pmol/L

36.18

294.54

198.77

507.75

179.32

421.42

87.78

356.28

-

-

-

451.7

TC, mmol/L

4.94

5.67

3.90

4.35

3.73

5.23

4.90

3.96

6.62

4.61

4.67

3.95

TG, mmol/L

1.20

0.82

0.47

1.15

0.51

1.10

0.59

2.14

4.01

2.18

2.12

0.42

LDL-c, mmol/L

1.94

2.85

2.01

2.50

1.97

2.85

3.37

2.07

3.31

2.63

2.19

2.31

HDL-c, mmol/L

2.04

1.85

1.10

0.93

1.09

1.41

1.01

0.69

1.03

0.89

0.82

1.09

UA, µmol/L

296

275

262

170

329

362

240

342

214

263

253

222

CRE, µmol/L

57

88

66

45

75

67

48

66

65

43

73

41

ACR, mg/g

7.59

331.23

7.40

98.44

0.05

1162.92

2.84

14.73

13.75

39.44

0.84

0.32

  1. aPatient with newly diagnosed diabetes
  2. bPatient with previously diagnosed diabetes
  3. cIndividual 15-01 was identified from patients with prediabetes
  4. SI/non-SI conversion calculate: glucose, mmol/L × 18.02 = mg/dl; insulin, pmol/L = µU/ml × 6.945; TC, mmol/L × 38.61 = mg/dl; TG, mmol/L × 88.50 = mg/dl; LDL, mmol/L × 38.61 = mg/dl; HDL, mmol/L × 38.61 = mg/dl; UA, µmol/L = mg/dl × 59.485; CRE, µmol/L = mg/dl × 88.4
  5. ACR urinary albumin/creatinine ratio, BMI body mass index, CRE serum creatinine, Fins fasting serum insulin, FPG fasting plasma glucose, GA glycated albumin, HbA1c hemoglobin A1c, HDL-c high-density lipoprotein cholesterol, LDL-c low-density lipoprotein cholesterol, N no, OHA oral hypoglycemic agents, Pins postprandial serum insulin, TC total cholesterol, TG triglyceride, UA uric acid, Y yes, 2-h PG 2-hour plasma glucose during 75 -g oral glucose tolerance test (OGTT)
Back to article page